|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12345678910111213...156157» |
- ||| Biomarker, Trial completion, Trial completion date, Trial primary completion date: PRECISESADS: Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: (clinicaltrials.gov) - May 30, 2018
P=N/A, N=2006, Completed, Sponsor: Fundación Pública Andaluza Progreso y Salud
Recruiting --> Completed | Trial completion date: Jan 2019 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2017
- | Trial completion, Enrollment change: ADIRA (Anti-inflammatory Diet In Rheumatoid Arthritis) (clinicaltrials.gov) - May 30, 2018
P=N/A, N=56, Completed, Sponsor: Göteborg University
Recruiting --> Completed | Trial completion date: Jan 2019 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2017 Recruiting --> Completed | N=80 --> 56
- ||| Biomarker, Trial completion, Trial completion date, Trial primary completion date: PRECISESADST: Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control (clinicaltrials.gov) - May 29, 2018
P=N/A, N=649, Completed, Sponsor: Fundaci
Recruiting --> Completed | N=80 --> 56 Recruiting --> Completed | Trial completion date: Jan 2019 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2017
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Ireland Natalizumab (TYSABRI) Observational Program (clinicaltrials.gov) - May 4, 2018
P=N/A, N=191, Completed, Sponsor: Biogen
Recruiting --> Completed | Trial completion date: Jan 2019 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2017 Active, not recruiting --> Completed
- ||| Trial completion, Trial completion date, Trial primary completion date: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - May 3, 2018
P=N/A, N=51, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018
- || Enrollment closed, Trial completion date, Trial primary completion date: Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study (clinicaltrials.gov) - May 3, 2018
P=N/A, N=120, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> May 2018
- | Trial primary completion date: CADI: Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care (clinicaltrials.gov) - May 3, 2018
P=N/A, N=20, Recruiting, Sponsor: University of Manitoba
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> May 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Enrollment closed, Trial completion date: FREE: A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2018
P=N/A, N=10, Active, not recruiting, Sponsor: University of Illinois at Chicago
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Oct 2017 --> May 2018
- || M923 (adalimumab biosimilar) / J&J
Enrollment change: Usability of an AI for M923 in Subjects With Moderate to Severe RA (clinicaltrials.gov) - May 1, 2018
P3, N=33, Completed, Sponsor: Momenta Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Oct 2017 --> May 2018 N=51 --> 33
- | Trial completion: NISSC: EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients (clinicaltrials.gov) - May 1, 2018
P=N/A, N=82, Completed, Sponsor: European Group for Blood and Marrow Transplantation
N=51 --> 33 Active, not recruiting --> Completed
- | tofacitinib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 30, 2018
P1, N=34, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: May 2020 --> Apr 2018 | Trial primary completion date: May 2020 --> Apr 2018
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Muscara: Doppler Evaluation in RA Patients After Adalimumab. (clinicaltrials.gov) - Apr 25, 2018
P4, N=60, Completed, Sponsor: Hamed Rezaei
Recruiting --> Completed | Trial completion date: May 2020 --> Apr 2018 | Trial primary completion date: May 2020 --> Apr 2018 Recruiting --> Completed | N=120 --> 60
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Walk SLE: Walk With Ease Program For Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 20, 2018
P=N/A, N=76, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=120 --> 60 Recruiting --> Active, not recruiting | N=50 --> 76 | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
- | Phase classification, Trial termination: Gene Expression in MS Patients Before and During Treatment With Interferon-beta (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=600, Terminated, Sponsor: S. Andrea Hospital
Recruiting --> Active, not recruiting | N=50 --> 76 | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018 Phase classification: P4 --> P=N/A | Completed --> Terminated; Few participants enrolled
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: GADD34-LES: Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=153, Active, not recruiting, Sponsor: University Hospital, Grenoble
Phase classification: P4 --> P=N/A | Completed --> Terminated; Few participants enrolled Recruiting --> Active, not recruiting | N=250 --> 153 | Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2018
- | oxcarbazepine / Generic mfg.
Trial completion: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2018
P2a, N=30, Completed, Sponsor: Queen Mary University of London
Recruiting --> Active, not recruiting | N=250 --> 153 | Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2018 Recruiting --> Completed
- | hydrocortisone / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes (clinicaltrials.gov) - Apr 18, 2018
P1, N=0, Withdrawn, Sponsor: Sansum Diabetes Research Institute
Recruiting --> Completed N=15 --> 0 | Trial completion date: Jun 2015 --> Jun 2020 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Jun 2020
- | Trial completion: Sequencing T-cells in Type I Diabetes Mellitus (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=40, Completed, Sponsor: Seton Healthcare Family
N=15 --> 0 | Trial completion date: Jun 2015 --> Jun 2020 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Jun 2020 Active, not recruiting --> Completed
- | Oshadi Icp (insulin oral) / Oshadi Drug Administration
Trial completion: Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study (clinicaltrials.gov) - Apr 18, 2018
P2, N=12, Completed, Sponsor: Oshadi Drug Administration
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: AT-thyro: Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=40, Completed, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 17, 2018
P1/2, N=104, Completed, Sponsor: University of British Columbia
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2017
- | Trial completion, Trial completion date, Trial primary completion date: CERT-MS: Cognitive and Emotion Regulation Training in MS (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=62, Completed, Sponsor: Ohio State University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2017 Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017
- || Remicade (infliximab) / J&J
Enrollment closed: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=140, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting
- ||| Trial completion: Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft (clinicaltrials.gov) - Apr 13, 2018
P=N/A, N=140, Completed, Sponsor: AlloSource
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: Strength Training to Improve Gait in People With Multiple Sclerosis (clinicaltrials.gov) - Apr 13, 2018
P=N/A, N=11, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 | Trial primary completion date: May 2018 --> Nov 2017
- | Enrollment change, Trial withdrawal: Progression of Cognitive and Physical Symptoms in Multiple Sclerosis (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 | Trial primary completion date: May 2018 --> Nov 2017 N=100 --> 0 | Enrolling by invitation --> Withdrawn
- | Trial completion: Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=101, Completed, Sponsor: Oregon Health and Science University
N=100 --> 0 | Enrolling by invitation --> Withdrawn Active, not recruiting --> Completed
- Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX (clinicaltrials.gov) - Apr 12, 2018
P4, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Active, not recruiting --> Completed N=20 --> 0
- | metformin / Generic mfg.
Trial completion: The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM (clinicaltrials.gov) - Apr 12, 2018
P4, N=30, Completed, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
N=20 --> 0 Recruiting --> Completed
- Byetta (exenatide) / AstraZeneca
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes (clinicaltrials.gov) - Apr 12, 2018
P2/3, N=10, Completed, Sponsor: Radboud University
Recruiting --> Completed Recruiting --> Completed | N=15 --> 10 | Trial completion date: Dec 2017 --> Apr 2018 | Trial primary completion date: Dec 2017 --> Mar 2018
- | Trial completion, Enrollment change: Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Apr 11, 2018
P=N/A, N=12, Completed, Sponsor: Odense University Hospital
Recruiting --> Completed | N=15 --> 10 | Trial completion date: Dec 2017 --> Apr 2018 | Trial primary completion date: Dec 2017 --> Mar 2018 Active, not recruiting --> Completed | N=20 --> 12
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 10, 2018
P3, N=359, Completed, Sponsor: UCB Pharma
Active, not recruiting --> Completed | N=20 --> 12 N=880 --> 359
- tibulizumab (ZB-106) / Zura Bio
Trial primary completion date: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Apr 10, 2018
P1, N=32, Active, not recruiting, Sponsor: Eli Lilly and Company
N=880 --> 359 Trial primary completion date: Mar 2018 --> Jul 2018
- |||| Tysabri (natalizumab) / Biogen, Royalty
Phase classification, Trial completion date, Trial primary completion date: Clinical Disease Activity With Long Term Natalizumab Treatment (clinicaltrials.gov) - Apr 9, 2018
P, N=277, Active, not recruiting, Sponsor: Biogen
Trial primary completion date: Mar 2018 --> Jul 2018 Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
- | Trial completion: Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2018
P=N/A, N=67, Completed, Sponsor: National University of Natural Medicine
Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed
- | Trial completion, Phase classification, Trial primary completion date: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Apr 9, 2018
P, N=148, Completed, Sponsor: McMaster University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial primary completion date: Dec 2016 --> Jun 2017
- | Phase classification, Enrollment change, MRI: Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 6, 2018
P, N=10, Completed, Sponsor: Optimus Clinical Research
Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial primary completion date: Dec 2016 --> Jun 2017 Phase classification: P=N/A --> P | N=20 --> 10
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Andosan-RA: Effect of Andosan in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=10, Completed, Sponsor: Egil Johnson
Phase classification: P=N/A --> P | N=20 --> 10 Recruiting --> Completed | N=15 --> 10 | Trial completion date: May 2017 --> Apr 2018 | Trial primary completion date: Dec 2016 --> Mar 2018
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Dissemination of the Lupus Interactive Navigator (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=541, Active, not recruiting, Sponsor: CHU de Quebec-Universite Laval
Recruiting --> Completed | N=15 --> 10 | Trial completion date: May 2017 --> Apr 2018 | Trial primary completion date: Dec 2016 --> Mar 2018 Not yet recruiting --> Active, not recruiting | N=2000 --> 541 | Trial completion date: Dec 2019 --> Sep 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
- | Phase classification, Enrollment change: Genetic Analysis of Psoriasis and Psoriatic Arthritis (clinicaltrials.gov) - Apr 6, 2018
P, N=2653, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting | N=2000 --> 541 | Trial completion date: Dec 2019 --> Sep 2018 | Trial primary completion date: Dec 2018 --> Jul 2018 Phase classification: P=N/A --> P | N=5000 --> 2653
- || Betaseron (IFN-β-1b) / Bayer
Phase classification: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (clinicaltrials.gov) - Apr 6, 2018
P, N=1085, Completed, Sponsor: Bayer
Phase classification: P=N/A --> P | N=5000 --> 2653 Phase classification: P=N/A --> P
- | Phase classification, Trial completion date, Trial primary completion date: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Apr 6, 2018
P, N=100, Recruiting, Sponsor: Claudio Gobbi
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion, HEOR: Joint Fitness: Exercise and Body Composition in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=33, Completed, Sponsor: Johns Hopkins University
Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed
- | Trial completion, Phase classification, Trial completion date, Trial primary completion date: Fibrocytes in Early and Longstanding Rheumatoid Arthritis (clinicaltrials.gov) - Apr 6, 2018
P, N=60, Completed, Sponsor: Odense University Hospital
Recruiting --> Completed Recruiting --> Completed | Phase classification: PN/A --> P | Trial completion date: Jan 2019 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2018
- | Trial completion, Phase classification, Trial completion date, Trial primary completion date: PosMTMS: The Impact of Positive Mental Training in Multiple Sclerosis (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=60, Completed, Sponsor: University of Edinburgh
Recruiting --> Completed | Phase classification: PN/A --> P | Trial completion date: Jan 2019 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2018 Not yet recruiting --> Completed | Phase classification: P2 --> PN/A | Trial completion date: Sep 2016 --> Jul 2017 | Trial primary completion date: Mar 2016 --> Jul 2017
- | Trial completion: Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=30, Completed, Sponsor: Oregon Health and Science University
Not yet recruiting --> Completed | Phase classification: P2 --> PN/A | Trial completion date: Sep 2016 --> Jul 2017 | Trial primary completion date: Mar 2016 --> Jul 2017 Active, not recruiting --> Completed
- | Plegridy (PEG-interferon β-1a) / Biogen
Trial completion: VITALITY: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy (clinicaltrials.gov) - Apr 6, 2018
P4, N=23, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- staphylococcal protein A (PRTX-100) / Protalex
Trial completion date, Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Apr 5, 2018
P1b, N=30, Recruiting, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
- ||| Trial completion, Phase classification, Trial completion date, Trial primary completion date: A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China (clinicaltrials.gov) - Apr 4, 2018
P=N/A, N=160, Completed, Sponsor: Johnson & Johnson Medical (Suzhou) Ltd.
Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | Trial completion date: Sep 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Dec 2017
- | Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: Three-dimensional Measurements of Diabetic Foot Ulcers (clinicaltrials.gov) - Apr 4, 2018
P, N=150, Active, not recruiting, Sponsor: Odense University Hospital
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | Trial completion date: Sep 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018